Karyopharm Therapeutics Inc.

Karyopharm targets $1 billion in peak U.S. revenue from selinexor in myelofibrosis, with Phase 3 SENTRY enrollment nearing completion. This represents a major market expansion beyond multiple myeloma, and analysts with buy ratings see transformative upside, reflected in an average price target of ~$53 from 11 analysts.

Despite ambitious revenue targets, selinexor's known toxicity profile remains a persistent concern. TipRanks' AI analyst flags weak financial fundamentals, persistent losses, negative free cash flow, and deeply negative equity — casting serious doubt on whether the myelofibrosis opportunity alone can reverse the company's financial trajectory.

Ongoing Phase 3 studies across multiple indications, including myelofibrosis and other cancers, suggest Karyopharm is actively working to optimize selinexor's usage and expand its addressable market. Analysts issuing buy ratings with a $16 price target see clinical progress as sufficient to justify a more constructive outlook.

Selinexor's toxicity has been cited as a fundamental barrier to profitability, with at least one analyst arguing the drug's side-effect burden makes it unlikely Karyopharm will ever achieve sustained profitability. This view, combined with competitive pressure in the multiple myeloma space, reinforces a sell rating.

Technical sentiment signals are constructive, with the stock trading above key moving averages and positive momentum. The latest earnings call reaffirmed FY25 guidance and highlighted meaningful clinical catalysts in Phase 3 studies, giving some analysts confidence that near-term milestones could unlock value ahead of a potential inflection point.

TipRanks' AI analyst highlights a short cash runway alongside deeply negative equity and negative free cash flow as major risks. With Q2 2026 consensus EPS at -$1.31 and expected revenue of only ~$33 million, the company faces significant financing risk that could dilute shareholders or limit its ability to complete costly Phase 3 programs.